Astellas Pharma, one of Japan's largest drugmakers, went public yesterday with a $1.1bn bid to buy CV Therapeutics, driving shares of the US biotechnology company above Astellas's offer price as investors bet the unsolicited approach would eventually yield a higher bid.
Astellas is looking to build critical mass in the cardiac treatment area by acquiring CV Therapeutics, which discovers and develops drugs that treat cardiovascular diseases.
More at FT
No comments:
Post a Comment